[1]
Sotoca Momblona, J.M. and Rovira-Illamola, M. 2023. Drug use evaluation of nirmatrelvir/ritonavir in three primary care centres during 2022. Ars Pharmaceutica (Internet). 64, 4 (Sep. 2023), 342–347. DOI:https://doi.org/10.30827/ars.v64i4.28499.